Korean J Otolaryngol-Head Neck Surg.  1999 Aug;42(8):950-954.

Expression of Ki-67 and Topoisomerase IIa in Human Middle Ear Cholesteatoma Epithelium

Affiliations
  • 1Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Korea University, Seoul, Korea.

Abstract

BACKGROUND AND OBJECTIVES: Cholesteatoma is a destructive lesion of the middle ear or mastoid process. The development of human cholesteatoma is due to the altered control of cellular proliferation in part, which tilts the balance toward the aggressive, invasive growth of squamous epithelium within the middle ear. Many efforts were performed to prove overproliferative characteristics of cholesteatoma using various proliferation markers. Nonetheless, trigger site of overproliferation within the overgrowing epithelium of cholesteatoma is still ill defined.
MATERIALS AND METHODS
In this study, we used the monoclonal antibody Ki-67 and Topoisomerase II, a marker of active proliferation, on frozen sections obtained from 12 cholesteatoma samples and observed expression of these markers in three different regions, from normal meatal skin, transitional zone and cholesteatoma sac.
RESULTS
The results were interpreted on the basis of nuclear staining and percentage of positively stained cells (labeling index). We found that labeling indices of cholesteatoma and transitional zone were significantly increased compared with that of normal meatal skin.
CONCLUSION
This result suggested that initiating of overproliliferation of cholesteatoma epithelium started from the transitional zone.

Keyword

Ki-67; Topoisomerase IIalpha; Cholesteatoma; Transitional zone

MeSH Terms

Cell Proliferation
Cholesteatoma
Cholesteatoma, Middle Ear*
DNA Topoisomerases, Type II
Ear, Middle*
Epithelium
Frozen Sections
Humans*
Mastoid
Skin
DNA Topoisomerases, Type II
Full Text Links
  • KJORL-HN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr